Want to see FR:ALVAL full AI Analyst Report?
ALVAL Stock Chart & Stats
€0.72
€0.05(3.27%)
At close: 4:00 PM EST
€0.72
€0.05(3.27%)
Day’s Range― - ―
52-Week Range€0.53 - €1.27
Previous CloseN/A
Volume46.53K
Average Volume (3M)112.19K
Market Cap
€30.20M
Enterprise Value€17.75M
Total Cash (Recent Filing)€8.68M
Total Debt (Recent Filing)€5.09M
Price to Earnings (P/E)―
Beta0.11
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.49
Shares Outstanding35,538,235
10 Day Avg. Volume162,174
30 Day Avg. Volume112,190
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)2.36
Price to Sales (P/S)18.17
P/FCF Ratio-2.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.33
Revenue Forecast (FY)€3.63M
Bulls Say, Bears Say
Bulls Say
Science-backed Nutraceutical FocusValbiotis’ concentrated strategy on plant-derived nutraceuticals for metabolic and cardiovascular indications builds durable competitive differentiation: scientific formulation, clear therapeutic niches, and consumer health channels can support repeatable sales, regulatory credibility, and partner interest over months.
Strong Recent Revenue ReboundA large reported revenue rebound signals growing commercial traction and product-market fit in core channels. If sustained, that growth can enable better fixed-cost absorption, improve gross margins over time, and validate commercialization capability versus peers in the consumer health space.
Manageable Leverage On Balance SheetReported leverage in the mid range implies the company has some structural capacity to use debt rather than immediate equity raises. Moderate reported debt reduces acute solvency pressure and gives more options for financing near-term operations or partnerships without immediate catastrophic balance-sheet risk.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow means the business is not self-financing and depends on external capital. Over a multi-month horizon this elevates dilution and execution risk, constrains marketing/R&D investment, and can force suboptimal financing or slower commercialization pacing.
Ongoing Operating Losses And Negative Gross ProfitNegative gross profit indicates product economics currently fail to cover direct costs, not just overhead. This structural issue prevents margin recovery unless pricing, COGS, or scale changes materially, and makes reaching sustainable profitability difficult without strategic reset or significant volume gains.
Shrinking Equity And Dilution RiskA declining equity base driven by recurring losses raises the likelihood of future capital raises and shareholder dilution. This reduces balance-sheet flexibility, limits ability to absorb shocks, and can weaken investor confidence, complicating medium-term funding and strategic execution.
Valbiotis SA News
ALVAL FAQ
What was Valbiotis SA’s price range in the past 12 months?
Valbiotis SA lowest stock price was €0.53 and its highest was €1.27 in the past 12 months.
What is Valbiotis SA’s market cap?
Valbiotis SA’s market cap is €30.20M.
When is Valbiotis SA’s upcoming earnings report date?
Valbiotis SA’s upcoming earnings report date is Sep 24, 2026 which is in 81 days.
How were Valbiotis SA’s earnings last quarter?
Valbiotis SA released its earnings results on Mar 02, 2026. The company reported -€0.2 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.2.
Is Valbiotis SA overvalued?
According to Wall Street analysts Valbiotis SA’s price is currently Overvalued.
Does Valbiotis SA pay dividends?
Valbiotis SA does not currently pay dividends.
What is Valbiotis SA’s EPS estimate?
Valbiotis SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Valbiotis SA have?
Valbiotis SA has 35,538,235 shares outstanding.
What happened to Valbiotis SA’s price movement after its last earnings report?
Valbiotis SA reported an EPS of -€0.2 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.96%.
Which hedge fund is a major shareholder of Valbiotis SA?
Currently, no hedge funds are holding shares in FR:ALVAL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Valbiotis SA
Valbiotis SA is a French company, established in 2014 and headquartered in Périgny, that specializes in the research and development of nutritional health products. Its primary focus is on preventing and managing metabolic and cardiovascular diseases. The company's pipeline includes several key candidates: TOTUM-63, currently in Phase II/III clinical trials for the treatment of type 2 diabetes; TOTUM-070, undergoing Phase II trials to address hypercholesterolemia; and TOTUM-854, which is in Phase II/III clinical development for arterial hypertension. Additionally, Valbiotis is developing TOTUM-448 to treat non-alcoholic fatty liver disease. The company maintains a strategic partnership with Nestlé Health Science.